Radiopharm Theranostics (RAD) Registration filing summary

Company overview and business model

• Focuses on developing and commercializing radiopharmaceutical products for therapeutic and diagnostic use in precision oncology, targeting radiosensitive solid tumors with high mortality rates.

• Operates a pipeline of six licensed platform technologies and a joint venture with MD Anderson, aiming to expand clinical trials and product candidates.

• Relies on partnerships with nuclear medicine suppliers and exclusive license agreements with leading institutions for access to novel technologies.

• Maintains a global intellectual property strategy, holding 31 patents and pursuing protection in key markets.

• No products are currently approved for commercial sale; all candidates are in preclinical or clinical development.

Financial performance and metrics

• Reported a total comprehensive loss of A$47.7 million for the year ended June 30, 2024, up from A$35.3 million in 2023, driven by lower R&D tax incentives and higher contingent consideration.

• Revenue from contracts with customers was A$299,228 in 2024, primarily from milestone payments.

• Cash and cash equivalents as of June 30, 2024, were A$18.6 million, with total assets of A$74.9 million and total liabilities of A$44.7 million.

• Research and development expenses increased to A$23.1 million in 2024, reflecting expanded clinical activities.

• Raised A$62.5 million in a two-tranche private placement in 2024, with additional equity and option issuances.

Use of proceeds and capital allocation

• Net proceeds from the 2024 private placement are allocated to advancing clinical trials, drug manufacturing, working capital, and general corporate purposes.

• Proceeds from option exercises will be used for similar operational needs; no dividends are anticipated in the foreseeable future.

• Cash runway is expected to fund operations until July 2026, but substantial additional funds will be required for long-term goals.